Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific insider Michel Lagarde filed a notice to sell 30,000 shares of common stock under Rule 144. The planned sale is through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 17,457,611.41 based on the figures provided.
The shares relate to an option originally granted on 07/20/2016 and acquired on 12/02/2025, with payment made in cash. Lagarde also sold 4,638 common shares in a prior transaction on 11/13/2025, generating gross proceeds of 2,756,934.80.
Thermo Fisher Scientific insider plans NYSE sale of option shares. A holder has filed a notice to sell 6,912 shares of Thermo Fisher Scientific common stock on the NYSE through Fidelity Brokerage Services. The shares were acquired on 12/02/2025 via the cash exercise of a stock option originally granted on 02/26/2019. Based on the filing, the aggregate market value of the planned sale is $4,022,369.28. The filing also notes that 375,708,059 common shares were outstanding and that the same seller disposed of 6,913 common shares on 12/01/2025 for gross proceeds of $4,131,761.84.
Thermo Fisher Scientific Inc., through its finance subsidiary Thermo Fisher Scientific (Finance I) B.V., issued €1,000,000,000 of Floating Rate Senior Notes due 2027 and €1,100,000,000 of 3.628% Senior Notes due 2035 in a public offering, fully and unconditionally guaranteed on a senior unsecured basis by the company. The notes were issued under an existing indenture and a new supplemental indenture, with quarterly interest on the floating rate notes and annual interest on the fixed rate notes.
The 2035 fixed rate notes are redeemable before a September 1, 2035 par call date at a make-whole redemption price and at par thereafter, and both series include a change-of-control put at 101% of principal plus accrued interest if the company undergoes a qualifying change of control with concurrent ratings downgrades. The company expects net proceeds of approximately €2.09 billion and intends to use them for general corporate purposes, including potential acquisitions, debt repayment or refinancing, working capital, capital spending, and share repurchases, or for temporary investment in short-term liquid instruments.
A shareholder of Thermo Fisher Scientific has filed a notice of proposed sale of 6,913 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $4,131,761.84 at the time of the notice. The filing lists an approximate sale date of 12/01/2025. These shares were acquired on 12/01/2025 through the cash exercise of an option that was originally granted on 02/26/2019. As context, the filing reports 375,708,059 shares of the issuer’s common stock outstanding.
Thermo Fisher Scientific Inc. (TMO) executive vice president Michael D. Shafer reported option exercises and related stock sales. On November 25, 2025, he exercised stock options for 8,475 shares at $253.99 and 2,250 shares at $294.02, then sold the same amounts of common stock at $600 per share.
These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the reported trades, Shafer directly beneficially owned 18,730.8026 shares of Thermo Fisher common stock, and the exercised options reported in this filing no longer remain outstanding.
Thermo Fisher Scientific (Finance I) B.V., fully guaranteed by Thermo Fisher Scientific Inc., is issuing €2,100,000,000 of senior euro-denominated notes, split between €1,000,000,000 floating rate notes due 2027 and €1,100,000,000 3.628% fixed rate notes due 2035. The floating notes pay 3‑month EURIBOR plus 0.280% with a zero floor and quarterly interest, while the fixed notes pay annual interest at 3.628%. Both issues are unsecured senior obligations and rank equally with other senior unsecured debt of the issuer and guarantor.
The notes are offered at 100% of principal, with underwriting discounts of 0.200% on the floating notes and 0.400% on the fixed notes, generating estimated net proceeds of about €2.09 billion. Thermo Fisher intends to use the cash for general corporate purposes, including potential acquisitions, debt repayment, capital spending, working capital or share repurchases, and may invest proceeds temporarily in short-term instruments. The company also highlights a pending $8.875 billion cash acquisition of Clario Holdings and a recent $2.48 billion U.S. dollar notes offering, underscoring ongoing balance sheet and strategic activity.
TMO received a Form 144 notice covering a planned sale of 10,725 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The filing lists an aggregate market value of 10,725 shares at 6,435,000.00 and notes that 375,708,059 shares of this class were outstanding.
The seller acquired these shares by exercising stock options granted on 02/26/2019 for 8,475 shares and on 09/05/2019 for 2,250 shares, with cash payment made on 11/25/2025. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Thermo Fisher Scientific (Finance I) B.V., a Dutch finance subsidiary of Thermo Fisher Scientific Inc., plans to issue euro-denominated floating-rate and fixed-rate senior notes fully and unconditionally guaranteed by Thermo Fisher. The floating notes will pay interest at 3‑month EURIBOR plus a spread with a zero floor, while the fixed notes pay a set annual coupon; both are unsecured senior obligations with no sinking fund.
Thermo Fisher intends to use the euro notes’ net proceeds for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, capital expenditures and share repurchases. The company recently agreed to acquire Clario Holdings, Inc. for $8.875 billion in cash plus up to $525 million of additional and contingent consideration, and in October 2025 issued $2.5 billion of U.S. dollar senior notes for similar corporate uses.
The notes are expected to be listed on the New York Stock Exchange and cleared through Euroclear and Clearstream. Key features include optional redemption for the fixed notes, tax-related redemption rights, a change-of-control repurchase at 101% of principal plus interest, and payment of additional amounts to address specified Dutch and U.S. withholding taxes.
Thermo Fisher Scientific Inc. (TMO) senior vice president and chief financial officer Stephen Williamson reported an insider transaction involving company common stock. On 11/14/2025, he transferred 433 shares of Thermo Fisher common stock in a transaction coded "G," which indicates a gift, at a reported price of $0 per share. Following this transaction, he beneficially owned 31,887.193 shares of common stock directly. He also had 12,674 shares reported as indirectly owned through a SLAT, and he disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Thermo Fisher Scientific (TMO) reported an insider transaction by its Sr. VP and Chief HR Officer. On 11/12/2025, the officer sold 1,057.577 shares of common stock at a price of $588.265 per share (Transaction Code S).
Following the sale, the officer’s beneficial ownership is 13,087.227 shares, held directly. No derivative securities were reported in this filing.